Aaron Louviere, NP
Family · Moultrie, GANPI 1689337800
Payments from drug & device makers
Across 264 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$574
- Dexcom, Inc.$533
- Bayer$529
- Boehringer Ingelheim$402
- Novo Nordisk$396
- AstraZeneca$354
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,580100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 36 | $574 |
| Dexcom, Inc. | 30 | $533 |
| Bayer | 26 | $529 |
| Boehringer Ingelheim | 23 | $402 |
| Novo Nordisk | 21 | $396 |
| AstraZeneca(2 entities) | 21 | $354 |
| Amgen | 13 | $202 |
| Johnson & Johnson | 12 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Pfizer | 7 | $135 |
| Merck | 7 | $116 |
| Exact Sciences | 5 | $91 |
| AbbVie | 5 | $82 |
| Novartis | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Vifor Pharma, Inc. | 3 | $73 |
| GSK | 4 | $72 |
| Phathom Pharmaceuticals, Inc. | 5 | $65 |
| Corcept Therapeutics | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $45 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $32 |
| Philips North America LLC | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$4,580 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 199 | $222,392 |
| JardianceEmpagliflozin | 127 | $163,443 |
| OzempicSemaglutide | 99 | $107,140 |
| TradjentaLinagliptin | 86 | $101,487 |
| JanuviaSitagliptin Phosphate | 75 | $72,127 |
| FarxigaDapagliflozin Propanediol | 57 | $57,067 |
| XareltoRivaroxaban | 41 | $50,338 |
| EliquisApixaban | 48 | $44,832 |
| RybelsusSemaglutide | 20 | $40,102 |
| TrintellixVortioxetine Hydrobromide | 21 | $28,088 |
| LinzessLinaclotide | 29 | $28,013 |
| Repatha SureclickEvolocumab | 19 | $12,864 |
| Dexlansoprazole DrDexlansoprazole | 33 | $12,368 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $8,836 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $402 | $264,930213 claims |
| Lilly USA, LLCMounjaro | $574 | $222,392199 claims |
| Novo NordiskOzempic, Rybelsus | $396 | $147,242119 claims |
| MerckJanuvia, Janumet Xr | $116 | $80,96489 claims |
| AstraZenecaFarxiga | $354 | $57,06757 claims |
| Johnson & JohnsonXarelto | $179 | $50,33841 claims |
| PfizerEliquis | $135 | $44,83248 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $162 | $28,08821 claims |
| AbbVieLinzess | $82 | $28,01329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Moultrie
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.